Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...
University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
Shamir Medical Center, Be'er Ya'aqov, Israel
Kasralainy Cairo University, Giza, Egypt
Baskent University Faculty of Medicine, Cankaya, Ankata, Turkey
Assiut university hospital, Assiut, Assuit, Egypt
Assiut University Hospitals, Assiut, Egypt
Northwestern University, Chicago, Illinois, United States
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
M D Anderson Cancer Center, Houston, Texas, United States
Ascension Genesys Hospital, Grand Blanc, Michigan, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.